866-997-4948(US-Canada Toll Free)

Hemophilia: Epidemiology Forecast to 2028

Published By :

GlobalData

Published Date : Jul 2019

Category :

Pharmaceutical

No. of Pages : 48 Pages

Hemophilia: Epidemiology Forecast to 2028

Summary

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B) (Bolton-Maggs and Pasi, 2003). The clinical presentation of hemophilia be at the mild, moderate, or severe stage, depending on the residual level of the circulating factor (White et al., 2001; Waure et al., 2012; Srivastava et al., 2013; Centers for Disease Control and Prevention, 2018a).

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the diagnosed prevalent cases of hemophilia A and hemophilia B in the 8MM. GlobalData epidemiologists applied country-specific prevalence rates of hemophilia A and hemophilia B, wherever available, to each countrys population to obtain the number of estimated diagnosed prevalent cases.

The following data describes epidemiology of hemophilia A and hemophilia B cases and acquired hemophilia cases. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B from 67,051 diagnosed prevalent cases in 2018 to 67,678 diagnosed prevalent cases in 2028, with an Annual Growth Rate (AGR) of 0.09% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 8MM, while Spain will have the lowest. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acquired hemophilia from 2,163 diagnosed prevalent cases in 2018 to 2,215 diagnosed prevalent cases in 2028, with an AGR of 0.24% during the forecast period. China will have the highest number of diagnosed prevalent cases of acquired hemophilia among the 8MM, while Spain will have the lowest.

Scope

- The Hemophilia Epidemiology Report provides an overview of the risk factors and global trends of hemophilia in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B are further segmented by severity (mild, moderate, and severe), inhibitors status, inhibitors severity (high responding and low responding), and type of treatment (prophylaxis and on-demand). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acquired hemophilia.
- The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
- Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
- Understand magnitude of hemophilia population by severity.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Hemophilia: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
3.4.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.4.7 Type of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.4.8 Diagnosed Prevalent Cases of Acquired Hemophilia
3.5 Epidemiological Forecast for Hemophilia A (2018-2028)
3.5.1 Diagnosed Prevalent Cases of Hemophilia A
3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
3.6 Epidemiological Forecast for Hemophilia B (2018-2028)
3.6.1 Diagnosed Prevalent Cases of Hemophilia B
3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
3.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2018-2028)
3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
3.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.7 Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
3.8 Discussion
3.8.1 Epidemiological Forecast Insight
3.8.2 Limitations of Analysis
3.8.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

1.1 List of Tables
Table 1: Relationship of Bleeding Severity with Clotting Factor Level.
Table 2: Comorbidities for Hemophilia

1.2 List of Figures
Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2018 and 2028
Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, All Ages, 2018 and 2028
Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), All Ages, 2018
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), All Ages, 2018
Figure 5: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 6: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 7: 8MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
Figure 8: 8MM, Sources Used, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 9: 8MM, Sources Used, Type of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 10: 8MM, Sources Used, Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, All Ages, Both Sexes, N, 2018
Figure 12: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, N, 2018
Figure 13: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, All Ages, N, 2018
Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2018
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, All Ages, Both Sexes, 2018
Figure 17: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, 2018
Figure 18: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, All Ages, N, 2018
Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 22: 8MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, 2018
Figure 23: 8MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2018
Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2018
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2018
Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 27: 8MM, Type of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2018
Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, All Ages, Both Sexes, N, 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *